search
Back to results

Trial of Written Exposure for Metastatic Cancer Patients (EASE)

Primary Purpose

Metastatic Cancer, Solid Tumor Cancer, Lymphoproliferative Disorders

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Written Exposure Therapy
Sponsored by
University of Colorado, Boulder
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Metastatic Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: At least 18 years of age English-speaking (able to speak, read, and write well in English) Diagnosed with solid tumor cancer at Stage III (locally metastatic) or Stage IV (distantly metastatic) or solid tumor cancer that has recurred, or actively treated lymphoproliferative cancer (e.g., non-solid tumor cancer) Report elevated cancer-related trauma symptoms or fear of cancer progression on the screening measures: IES-R, FoP-Q 12-item short version. No moderate to severe dementia reported by patient or seen during eligibility confirmation in the medical chart Are capable at time of consent of understanding and voluntarily consenting themselves to the study, attending EASE sessions, and completing the online sessions at home, confirmed by an Eastern Cooperative Group Performance Status Scale of 0 to 2. Given that the study does not require individuals to leave their home, we will make an exception for individuals endorsing an Eastern Cooperative Group Performance Status Scale score of 3 (confined to bed or chair for <50% of waking hours, able to do only limited selfcare) if they meet all other study criteria, including criteria 7. Report that they are able and willing to complete all study procedures, including the online assessments and the intervention itself, including being physically able to write by hand or type for 30 minutes at a time and do weekly hour-long EASE sessions by Zoom. Has access to a computer with internet connection or are willing to use a study-loaned computer tablet for the study duration, and are willing to conduct sessions via videoconferencing on a computer Exclusion Criteria: 1. Current moderate or high suicide risk evaluated by the Columbia Suicide Severity Rating Scale (CSSRS)

Sites / Locations

  • University of Colorado BoulderRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EASE Written Exposure Intervention

Arm Description

Assigned Intervention

Outcomes

Primary Outcome Measures

Cancer-related trauma symptoms
A primary outcome will be change in cancer-related trauma symptoms, assessed by the 22-item Impact of Events Scale-Revised. Possible scores range 0-88 with higher scores indicating greater distress/bother.
Fear of cancer progression
A primary outcome will be change in fear of cancer progression, assessed by the 12-item Fear of Progression Questionnaire - Short Form and by the four general scale items from the Concerns about Recurrence Scale, with wording adapted to focus on cancer progression rather than recurrence. Range: 12-60, higher scores are associated with higher fear of cancer progression.
Intervention acceptability
Assessed with the Acceptability of Intervention Scale. Possible scores range from 4-20, with higher scores indicating greater intervention acceptability.
Intervention Feasibility
For participants who begin the intervention, at least 70% complete all intervention sessions

Secondary Outcome Measures

Patient Health Questionnaire (PHQ-8)
Patient-reported depression symptom questionnaire. Range is 0 to 24. Higher scores indicate more depression symptoms
Generalized Anxiety Disorder-7 Questionnaire
Patient-reported anxiety symptom questionnaire. Possible scores range from 0-21, with higher scores indicating more anxiety symptoms
The Death Attitude Profile-Revised, Fear of Death and Death Avoidance Scales
Patient-reported fear of death and dying questionnaire. Possible scores range from 12-84, with higher scores indicating greater fear of death and dying
Hopelessness Assessment in Illness Questionnaire 8-item
Patient-reported hopelessness specifically intended for use with adults with incurable cancer. Possible scores range 0-16, with higher scores indicating greater hopelessness.
The Patient Reported Outcome Measurement Information System (PROMIS) Fatigue-Short Form v1.0
Patient-reported levels of fatigue. Possible scores range 6-30, with higher scores indicating greater fatigue.
The Patient Reported Outcome Measurement Information System (PROMIS) Pain Interference-Short Form v1.0
Patient-reported dimension of pain interference (e.g., the extent to which pain interferes with daily life and life roles). Possible scores range 6-30, with higher scores indicating greater pain.
Emotional Approach Coping Scale (COPE): Avoidance coping (process measure)
Patient-reported coping through avoidance using three avoidance coping scales (mental disengagement, denial, physical disengagement) with cancer as the anchor. Possible scores range 8-28, with higher scores indicating greater denial, mental and behavioral disengagement.
Five Factor Mindfulness Questionnaire, Nonjudge and nonreact scales (process measure)
Patient-reported coping through acceptance. Possible scores range 15-75, with higher scores reflecting greater nonreactivity and nonjudging of inner experience.
Valuing Questionnaire
Valued engagement in daily life. Possible scores range 0-30 for each of the two subscales with higher scores indicating greater engagement and sense of purpose in life.
Self-compassion Scale-Short Form
Self-compassion questionnaire. Possible scores range 12-60 with higher scores indicating higher self-compassion.

Full Information

First Posted
May 16, 2022
Last Updated
September 13, 2023
Sponsor
University of Colorado, Boulder
Collaborators
University of Colorado, Denver
search

1. Study Identification

Unique Protocol Identification Number
NCT06042400
Brief Title
Trial of Written Exposure for Metastatic Cancer Patients (EASE)
Official Title
Pilot Trial of Written Exposure Intervention for Metastatic Cancer Patients: The EASE Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 18, 2022 (Actual)
Primary Completion Date
April 18, 2024 (Anticipated)
Study Completion Date
October 18, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Colorado, Boulder
Collaborators
University of Colorado, Denver

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and hopelessness, as well as physical symptoms such as fatigue and pain. Cancer patients may report feeling upset or haunted by imagined scenarios in a way that causes them distress and lowers their quality of life. This study aims to look at the acceptability and feasability of a writing-based intervention for adults with late-stage or recurrent cancer, or actively treated blood cancer. The EASE study uses a writing-based approach to address an individual's worst-case scenario about cancer because previous studies have shown that similar approaches have shown promise in reducing fear in early-stage cancer survivors and among adults with PTSD (posttraumatic stress disorder). The EASE study represents a novel adaptation of this foundational work on written exposure therapy (WET) to address worst-case scenarios among adults with late stage cancers. The EASE study will include 5 weekly one-on-one online video sessions with a trained therapist where participants will be coached through writing exercises based on a worst-case scenario related to their cancer experience.
Detailed Description
This single-arm pilot trial aims to look at the acceptability and feasibility of a writing-based intervention for adults with metastatic or recurrent cancer, or actively treated blood cancer. The EASE intervention represents a novel adaptation of foundational work on written exposure therapy (WET) to address worst-case scenarios among adults with metastatic cancer, including cancer diagnosed at Stage III or IV, cancer that has recurred, or actively treated lymphoproliferative cancer. The study will consist of 5 weekly one-on-one online sessions with a trained graduate student therapist who will explain the approach and coach participants through writing exercises based on a worst-case scenario related to their fears about cancer. Remote Delivery. The intervention will be delivered remotely via videoconferencing software or videoconferencing plus phone. Phone sessions will be available as a backup if a participant has significant technical difficulties with Zoom. All sessions will be recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Cancer, Solid Tumor Cancer, Lymphoproliferative Disorders, Anxiety, Post-traumatic Stress Symptoms, Fear of Cancer Progression

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single-arm pilot trial: all participants will receive intervention
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
EASE Written Exposure Intervention
Arm Type
Experimental
Arm Description
Assigned Intervention
Intervention Type
Behavioral
Intervention Name(s)
Written Exposure Therapy
Intervention Description
An innovative written exposure therapy intervention that addresses psychosocial needs commonly experienced by patients with late stage cancers.
Primary Outcome Measure Information:
Title
Cancer-related trauma symptoms
Description
A primary outcome will be change in cancer-related trauma symptoms, assessed by the 22-item Impact of Events Scale-Revised. Possible scores range 0-88 with higher scores indicating greater distress/bother.
Time Frame
Assessed seven times: prior to the intervention (Pre), before each intervention session, 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
Fear of cancer progression
Description
A primary outcome will be change in fear of cancer progression, assessed by the 12-item Fear of Progression Questionnaire - Short Form and by the four general scale items from the Concerns about Recurrence Scale, with wording adapted to focus on cancer progression rather than recurrence. Range: 12-60, higher scores are associated with higher fear of cancer progression.
Time Frame
Assessed: prior to the intervention (Pre), before each intervention session, 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
Intervention acceptability
Description
Assessed with the Acceptability of Intervention Scale. Possible scores range from 4-20, with higher scores indicating greater intervention acceptability.
Time Frame
Assessed in order to compare values at 2 timepoints: 6 weeks after baseline (Post) and separately at 1.5-month follow-up (FU)
Title
Intervention Feasibility
Description
For participants who begin the intervention, at least 70% complete all intervention sessions
Time Frame
Assessed at each intervention session 1-5, 1 to 5 weeks after baseline.
Secondary Outcome Measure Information:
Title
Patient Health Questionnaire (PHQ-8)
Description
Patient-reported depression symptom questionnaire. Range is 0 to 24. Higher scores indicate more depression symptoms
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post),, at 1.5 and 3-month follow-up (FU)
Title
Generalized Anxiety Disorder-7 Questionnaire
Description
Patient-reported anxiety symptom questionnaire. Possible scores range from 0-21, with higher scores indicating more anxiety symptoms
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
The Death Attitude Profile-Revised, Fear of Death and Death Avoidance Scales
Description
Patient-reported fear of death and dying questionnaire. Possible scores range from 12-84, with higher scores indicating greater fear of death and dying
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
Hopelessness Assessment in Illness Questionnaire 8-item
Description
Patient-reported hopelessness specifically intended for use with adults with incurable cancer. Possible scores range 0-16, with higher scores indicating greater hopelessness.
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
The Patient Reported Outcome Measurement Information System (PROMIS) Fatigue-Short Form v1.0
Description
Patient-reported levels of fatigue. Possible scores range 6-30, with higher scores indicating greater fatigue.
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
The Patient Reported Outcome Measurement Information System (PROMIS) Pain Interference-Short Form v1.0
Description
Patient-reported dimension of pain interference (e.g., the extent to which pain interferes with daily life and life roles). Possible scores range 6-30, with higher scores indicating greater pain.
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
Emotional Approach Coping Scale (COPE): Avoidance coping (process measure)
Description
Patient-reported coping through avoidance using three avoidance coping scales (mental disengagement, denial, physical disengagement) with cancer as the anchor. Possible scores range 8-28, with higher scores indicating greater denial, mental and behavioral disengagement.
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
Five Factor Mindfulness Questionnaire, Nonjudge and nonreact scales (process measure)
Description
Patient-reported coping through acceptance. Possible scores range 15-75, with higher scores reflecting greater nonreactivity and nonjudging of inner experience.
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
Valuing Questionnaire
Description
Valued engagement in daily life. Possible scores range 0-30 for each of the two subscales with higher scores indicating greater engagement and sense of purpose in life.
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Title
Self-compassion Scale-Short Form
Description
Self-compassion questionnaire. Possible scores range 12-60 with higher scores indicating higher self-compassion.
Time Frame
Assessed: prior to the intervention (Pre), 3 weeks after the intervention begins (Mid), 6 weeks after baseline (Post), at 1.5 and 3-month follow-up (FU)
Other Pre-specified Outcome Measures:
Title
Intervention Acceptability: Session Feedback Questionnaire
Description
Participant value of the session will be assessed through the Session Feedback. Possible scores range 4-20, with higher scores indicating higher value and acceptability of the session.
Time Frame
Once weekly during intervention period from Pre to Post (6 weeks after baseline, e.g., at the end of each weekly session during the intervention period)
Title
Intervention Acceptability: Client Satisfaction Questionnaire-8
Description
Participant satisfaction will be measured using the Client Satisfaction Questionnaire-8 (adapted to the current intervention). Possible scores range 8-32, with higher scores indicating more satisfaction.
Time Frame
Assessed and reported two times: 6 weeks after baseline (Post), 3-month follow-up (FU)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 18 years of age English-speaking (able to speak, read, and write well in English) Diagnosed with solid tumor cancer at Stage III (locally metastatic) or Stage IV (distantly metastatic) or solid tumor cancer that has recurred, or actively treated lymphoproliferative cancer (e.g., non-solid tumor cancer) Report elevated cancer-related trauma symptoms or fear of cancer progression on the screening measures: IES-R, FoP-Q 12-item short version. No moderate to severe dementia reported by patient or seen during eligibility confirmation in the medical chart Are capable at time of consent of understanding and voluntarily consenting themselves to the study, attending EASE sessions, and completing the online sessions at home, confirmed by an Eastern Cooperative Group Performance Status Scale of 0 to 2. Given that the study does not require individuals to leave their home, we will make an exception for individuals endorsing an Eastern Cooperative Group Performance Status Scale score of 3 (confined to bed or chair for <50% of waking hours, able to do only limited selfcare) if they meet all other study criteria, including criteria 7. Report that they are able and willing to complete all study procedures, including the online assessments and the intervention itself, including being physically able to write by hand or type for 30 minutes at a time and do weekly hour-long EASE sessions by Zoom. Has access to a computer with internet connection or are willing to use a study-loaned computer tablet for the study duration, and are willing to conduct sessions via videoconferencing on a computer Exclusion Criteria: 1. Current moderate or high suicide risk evaluated by the Columbia Suicide Severity Rating Scale (CSSRS)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elizabeth Slivjak, MA
Phone
‪720-340-3273‬
Email
elizabeth.slivjak@colorado.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Madeline Nealis, MPH
Phone
720-515-9461
Email
valuedliving@colorado.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joanna Arch, PhD
Organizational Affiliation
University of Colorado, Boulder
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Boulder
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80309
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Trial of Written Exposure for Metastatic Cancer Patients (EASE)

We'll reach out to this number within 24 hrs